Aclarion Inc (ACON)vsVeeva Systems Inc Class A (VEEV)
ACON
Aclarion Inc
$2.52
-4.55%
HEALTHCARE · Cap: $6.98M
VEEV
Veeva Systems Inc Class A
$260.21
-1.34%
HEALTHCARE · Cap: $42.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 4127986% more annual revenue ($3.46B vs $83,770). VEEV leads profitability with a 29.3% profit margin vs 0.0%. VEEV earns a higher WallStSmart Score of 66/100 (B-).
ACON
Avoid33
out of 100
Grade: F
VEEV
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+41.1%
Fair Value
$300.79
Current Price
$260.21
$40.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 30.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Strong operational efficiency at 29.6%
17.6% revenue growth
Earnings expanding 39.5% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.
Bull Case : VEEV
The strongest argument for VEEV centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 29.3% and operating margin at 29.6%. Revenue growth of 17.6% demonstrates continued momentum.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio. A P/E of 43.4x leaves little room for execution misses.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while VEEV is a growth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.24 — expect wider price swings.
ACON is growing revenue faster at 30.5% — sustainability is the question.
VEEV generates stronger free cash flow (231M), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (66/100 vs 33/100), backed by strong 29.3% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a pioneering healthcare technology firm dedicated to advancing non-invasive diagnostic solutions for musculoskeletal conditions through cutting-edge imaging and data analytics. By harnessing the power of machine learning, Aclarion empowers healthcare providers with actionable insights that not only improve clinical outcomes but also optimize treatment pathways and reduce costs. Positioned at the forefront of the digital health revolution, the company is well-equipped to meet the rising demand for effective diagnostics, thereby significantly enhancing patient management and care standards in a dynamic healthcare landscape. Aclarion's commitment to improving patient care underscores its vital role in the future of healthcare delivery.
Visit Website →Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?